1
|
Carroll AR, Copp BR, Grkovic T, Keyzers RA, Prinsep MR. Marine natural products. Nat Prod Rep 2024; 41:162-207. [PMID: 38285012 DOI: 10.1039/d3np00061c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2024]
Abstract
Covering: January to the end of December 2022This review covers the literature published in 2022 for marine natural products (MNPs), with 645 citations (633 for the period January to December 2022) referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, the submerged parts of mangroves and other intertidal plants. The emphasis is on new compounds (1417 in 384 papers for 2022), together with the relevant biological activities, source organisms and country of origin. Pertinent reviews, biosynthetic studies, first syntheses, and syntheses that led to the revision of structures or stereochemistries, have been included. An analysis of NP structure class diversity in relation to biota source and biome is discussed.
Collapse
Affiliation(s)
- Anthony R Carroll
- School of Environment and Science, Griffith University, Gold Coast, Australia.
- Griffith Institute for Drug Discovery, Griffith University, Brisbane, Australia
| | - Brent R Copp
- School of Chemical Sciences, University of Auckland, Auckland, New Zealand
| | - Tanja Grkovic
- Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, and Molecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA
| | - Robert A Keyzers
- Centre for Biodiscovery, and School of Chemical and Physical Sciences, Victoria University of Wellington, Wellington, New Zealand
| | | |
Collapse
|
2
|
Bossuat M, Rullière P, Preuilh N, Peixoto A, Joly E, Gomez JG, Bourkhis M, Rodriguez F, Gonçalves F, Fabing I, Gaspard H, Bernardes-Génisson V, Maraval V, Ballereau S, Chauvin R, Britton S, Génisson Y. Phenyl dialkynylcarbinols, a Bioinspired Series of Synthetic Antitumor Acetylenic Lipids. J Med Chem 2023; 66:13918-13945. [PMID: 37816126 DOI: 10.1021/acs.jmedchem.3c00859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/12/2023]
Abstract
A series of 25 chiral anti-cancer lipidic alkynylcarbinols (LACs) were devised by introducing an (hetero)aromatic ring between the aliphatic chain and the dialkynylcarbinol warhead. The resulting phenyl-dialkynylcarbinols (PACs) exhibit enhanced stability, while retaining cytotoxicity against HCT116 and U2OS cell lines with IC50 down to 40 nM for resolved eutomers. A clickable probe was used to confirm the PAC prodrug behavior: upon enantiospecific bio-oxidation of the carbinol by the HSD17B11 short-chain dehydrogenase/reductase (SDR), the resulting ynones covalently modify cellular proteins, leading to endoplasmic reticulum stress, ubiquitin-proteasome system inhibition, and apoptosis. Insights into the design of LAC prodrugs specifically bioactivated by HSD17B11 vs its paralogue HSD17B13 were obtained. The HSD17B11/HSD17B13-dependent cytotoxicity of PACs was exploited to develop a cellular assay to identify specific inhibitors of these enzymes. A docking study was performed with the HSD17B11 AlphaFold model, providing a molecular basis of the SDR substrates mimicry by PACs. The safety profile of a representative PAC was established in mice.
Collapse
Affiliation(s)
- Margaux Bossuat
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
- LCC-CNRS, Université de Toulouse, CNRS UPR 8241, UPS, F-31077 Toulouse, France
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III─Paul Sabatier (UT3), F-31044 Toulouse, France
| | - Pauline Rullière
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| | - Nadège Preuilh
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III─Paul Sabatier (UT3), F-31044 Toulouse, France
| | - Antonio Peixoto
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III─Paul Sabatier (UT3), F-31044 Toulouse, France
| | - Etienne Joly
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III─Paul Sabatier (UT3), F-31044 Toulouse, France
| | - Jean-Guillaume Gomez
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| | - Maroua Bourkhis
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| | - Frédéric Rodriguez
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| | - Fernanda Gonçalves
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| | - Isabelle Fabing
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| | - Hafida Gaspard
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| | | | - Valérie Maraval
- LCC-CNRS, Université de Toulouse, CNRS UPR 8241, UPS, F-31077 Toulouse, France
| | - Stéphanie Ballereau
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| | - Remi Chauvin
- LCC-CNRS, Université de Toulouse, CNRS UPR 8241, UPS, F-31077 Toulouse, France
| | - Sébastien Britton
- Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, Université Toulouse III─Paul Sabatier (UT3), F-31044 Toulouse, France
| | - Yves Génisson
- Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intérêt Biologique (SPCMIB), UMR 5068, CNRS, Université Paul Sabatier-Toulouse III, F-31062 Toulouse, France
| |
Collapse
|